Compare Ford Motor Company (F) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Neurocrine Biosciences Inc — how do they compare? Ford Motor Company trades at $14.22 (market cap $56.50B), while Neurocrine Biosciences Inc trades at $171.33 (market cap $17.30B). The key difference: Ford Motor Company is far larger — about 3.3× Neurocrine Biosciences Inc's market cap, and Ford Motor Company pays a 4.23% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| F | NBIX | |
|---|---|---|
Market Cap | $56.50B | $17.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $180.55 |
52-Week Low | $10.82 | $123.10 |
Enterprise Value | $185.53B | $16.39B |
Dividend Yield | 4.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford (F) trades at $13.93, up 0.44% on the day, with a neutral technical outlook and mixed fundamental signals. The company reported a net loss of $8.18 billion in 2025 despite revenue growth to $187.27 billion, reflecting margin pressure. Recent news highlights labor agreements, EV initiatives, and a 4%+ dividend yield. Analyst consensus is a $15.00 price target with a Hold-heavy rating distribution.
The stock presents a value opportunity with low P/E and P/S ratios, but significant risks include persistent net losses, high debt levels, and competitive pressures in the EV transition. Upside depends on execution of cost controls and successful new product launches, particularly in electric vehicles.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
